Please select the option that best describes you:

How would you approach patients with ALK-positive metastatic NSCLC who progress on crizotinib and subsequently alectinib?   

In the absence of clinical trial, is there are role for dose-escalating alectinib, or would you consider brigatinib or chemotherapy?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Center for Hematology and Oncology
Are there particular companies that are good at de...
Sign in or Register to read more